Respiratory Complications of Parkinson's Disease

Holly Shill; Mark Stacy

doi:10.1055/s-2002-33034

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2002; 23(3): 261-266
DOI: 10.1055/s-2002-33034

Respiratory Complications of Parkinson's Disease

Holly Shill¹ , Mark Stacy²

¹Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
²Muhammad Ali Parkinson Research Center, Barrow Neurological Institute, Phoenix, Arizona

Abstract

ABSTRACT

Patients with Parkinson's disease are at risk for pulmonary complications as a consequence of both the underlying disease pathology and the side effects of medication. Degeneration of the substantia nigra and subsequent loss of dopaminergic neurons may produce changes in ventilatory parameters. Upper airway obstruction and chest wall restriction are both common, and both may respond to levodopa. However, therapy for Parkinson's may also contribute to pulmonary morbidity. Overtreatment with levodopa causes respiratory dyskinesia that may be difficult to differentiate from complications of the disease itself. Therapy with ergot derivatives may cause pleuropulmonary fibrosis. Pneumonia resulting from the respiratory complications remains a significant cause of morbidity and mortality in Parkinson's disease.

KEYWORDS

Parkinson's disease - dopaminergic - levodopa - chest wall rigidity - pulmonary complications

Full Text

References

REFERENCES

1 Parkinson J. An essay on the shaking palsy. London: Sherwood, Nealy and Jones; 1817
2 Hoehn M M, Yahr M D. Parkinsonism: onset, progression and mortality. Neurology . 1967; 17 427-442
3 Schwab R D, England A C, Peterson E. Akinesia in Parkinson's disease. Neurology . 1959; 9 65-72
4 Baker K K, Ramig L O, Luschei E S, Smith M E. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology . 1998; 51 1592-1598
5 Jankovic J, Cardoso F, Grossman R G, Hamilton W J. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery . 1995; 37 680-687
6 Lang A E, Duff J, Saint-Cyr J A. Posteroventral medial pallidotomy in Parkinson's disease. J Neurol . 1999; S28-S41
7 Berke G S, Gerratt B, Kreiman J, Jackson K. Treatment of Parkinson hypophonia with percutaneous collagen augmentation. Laryngoscope . 1999; 109 1295-1299
8 Hovestadt A, Bogaard J M, Meerwaldt J D. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry . 1989; 52 329-333
9 Fontana G A, Pantaleo T, Lavorini F. Defective motor control of coughing in Parkinson's disease. Am J Respir Crit Care Med . 1998; 158 458-464
10 Vincken W G, Gauthier S G, Dollfuss R E. Involvement of upper-airway muscles in extrapyramidal disorders: a cause of airflow limitation. N Engl J Med . 1984; 311 438-442
11 Neu H C, Connolly Jr J J, Schwertley F W. Obstructive respiratory dysfunction in parkinsonian patients. Am Rev Respir Dis . 1967; 95 33-47
12 Izquierdo-Alonso J L, Jimenez-Jimenez F J, Cabrera-Valdivia F, Mansilla-Lesmes M. Airway dysfunction in patients with Parkinson's disease. Lung . 1994; 172 47-55
13 Kinnier-Wilson S A. Neurology. Baltimore, Md: Willams & Wilkins; 1940
14 Sabate M, Gonzalez I, Ruperez F, Rodriguez M. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. J Neurol Sci . 1996; 138 114-119
15 de Bruin F P, de Bruin M V, Lees A J, Pride N B. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease. Am Rev Respir Dis . 1993; 148 1576-1580
16 Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson's disease. Chest . 2001; 119(2) 387-393
17 Read D, Young A. Stridor and parkinsonism. Postgrad Med J . 1983; 59 520-521
18 Fink M E, Klebanoff L M, Lennihan L, Fahn S. Acute respiratory failure during drug manipulation in patients with Parkinson's disease. Neurology . 1989; 39 348
19 Riley D E, Grossman G, Martin L. Acute respiratory failure from dopamine agonist withdrawal. Neurology . 1992; 42 1843-1844
20 Easdown L J, Tessler M J, Minuk J. Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure. Can J Anaesth . 1995; 42 344-347
21 Galvez-Jimenez N, Lang A E. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci . 1996; 23 198-203
22 Nugent C A, Harris H W, Cohn J. Dyspnea as a symptom in Parkinson's syndrome. Am Rev Tuberc . 1958; 78 682-691
23 Paulson G D, Tafrate R H. Some ``minor'' aspects of parkinsonism, especially pulmonary function. Neurology . 1970; 20 14-17
24 Bateman D N, Cooper R G, Gibson G J. Levodopa dosage and ventilatory function in Parkinson's disease. Br Med J (Clin Res Ed) . 1981; 283 190-191
25 Estenne M, Hubert M, De Troyer A. Respiratory-muscle involvement in Parkinson's disease. N Engl J Med . 1984; 311 1516-1517
26 Sabate M, Rodriguez M, Mendez E. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson's disease. Arch Phys Med Rehabil . 1996; 77 29-34
27 Apps M C, Sheaff P C, Ingram D A. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry . 1985; 48 1240-1245
28 Silber M H, Levine S. Stridor and death in multiple system atrophy. Mov Disord . 2000; 15 699-704
29 Chester C S, Gottfried S B, Cameron D I, Strohl K P. Pathophysiological findings in a patient with Shy-Drager and alveolar hypoventilation syndromes. Chest . 1988; 94 212-214
30 Weiner W J, Goetz C G, Nausieda P A, Klawans H L. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med . 1978; 88 327-331
31 Zupnick H M, Brown L K, Miller A, Moros D A. Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography. Am J Med . 1990; 89 109-114
32 Hartman D E. Stridor during dystonia phases of Parkinson's disease. J Neurol Neurosurg Psychiatry . 1988; 51 161
33 Vazquez A, Jimenez-Jimenez F J, Garcia-Ruiz P, Garcia-Urra D. ``Panic attacks'' in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand . 1993; 87 14-18
34 Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy . 2000; 20(suppl 1, pt 2) S8-S16
35 Bhatt M H, Keenan S P, Fleetham J A, Calne D B. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol . 1991; 30 613-616
36 Geminiani G, Fetoni V, Genitrini S. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord . 1996; 11 495-500
37 McElvaney N G, Wilcox P G, Churg A, Fleetham J A. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med . 1988; 148 2231-2236
38 Todman D H, Oliver W A, Edwards R L. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol . 1990; 27 79-82
39 LeWitt P A, Calne D B. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet . 1981; 1 44-45
40 Hillerdal G, Lee J, Blomkvist A. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J . 1997; 10 2711-2715
41 Canning C G, Alison J A, Allen N E, Groeller H. Parkinson's disease: an investigation of exercise capacity, respiratory function, and gait. Arch Phys Med Rehabil . 1997; 78 199-207
42 Koseoglu F, Inan L, Ozel S. The effects of a pulmonary rehabilitation program on pulmonary function tests and exercise tolerance in patients with Parkinson's disease. Funct Neurol . 1997; 12 319-325
43 Tzelepis G E, McCool F D, Friedman J H, Hoppin Jr G F. Respiratory muscle dysfunction in Parkinson's disease. Am Rev Respir Dis . 1988; 138 266-271